Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Cancer Res Commun. 2022 Jul 26;2022:10.1158/2767-9764.CRC-21-0143. doi: 10.1158/2767-9764.CRC-21-0143

Figure 1. Best overall response.

Figure 1.

A) ORR data for all patients and by disease category for patients treated with either ICI monotherapy or chemo/ICI combination therapy. B) ORR data for all patients and by disease category for patients treated with ICI monotherapy. C) ORR data for NSCLC patients stratified by PD-L1 status treated with ICI monotherapy. Only patients for whom PD-L1 was known were included. CR- complete response; PR- partial response; SD- stable disease; PD- progressive disease.